Molecular Markers of Chemotherapy Toxicity in Colorectal Cancer

被引：2

作者：

Braun, Michael S. ^{[1
]}

Seymour, Matthew T. ^{[1
]}

机构：

[1] Univ Leeds, Leeds Inst Mol Med, Sect Oncol & Clin Res, Leeds, W Yorkshire, England

来源：

CURRENT COLORECTAL CANCER REPORTS | 2011年 / 7卷 / 01期

关键词：

Fluorouracil; Irinotecan; Oxaliplatin; Pharmacogenomics; Toxicity; Colorectal;

D O I：

10.1007/s11888-010-0078-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Personalized medicine appears to be the inevitable consequence of improvements in our understanding of the mechanisms of action of chemotherapeutic agents, as well as the description of the human genome and its impact on our understanding of the genes involved in DNA repair and drug metabolism. These rapid developments have been associated with the first efforts to establish genetic predictors of chemotherapy efficacy and toxicity for the chemotherapy drugs active in colorectal cancer-fluorouracil, irinotecan, and oxaliplatin.

引用

页码：105 / 111

页数：7

共 38 条

[1] Rouits E., Boisdron-Celle M., Dumont A., Guerin O., Morel A., Gamelin E., Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: A molecular and clinical study of 75 patients, Clinical Cancer Research, 10, 15, pp. 5151-5159, (2004)
[2] Van Kuilenburg A.B., Meinsma R., Zoetekouw L., Van Gennip A.H., High prevalence of the IVS14+1 G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity, Pharmacogenetics, 12, 7, pp. 555-558, (2002)
[3] Johnston P.G., Fisher E.R., Rockette H.E., Fisher B., Wolmark N., Drake J.C., Chabner B.A., Allegra C.J., The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer, Journal of Clinical Oncology, 12, 12, pp. 2640-2647, (1994)
[4] Longley D.B., Harkin D.P., Johnston P.G., 5-Fluorouracil: Mechanisms of action and clinical strategies, Nature Reviews Cancer, 3, 5, pp. 330-338, (2003)
[5] Collie-Duguid E.S.R., Etienne M.C., Milano G., McLeod H.L., Known variant DPYD alleles do not explain DPD deficiency in cancer patients, Pharmacogenetics, 10, 3, pp. 217-223, (2000)
[6] Ridge S.A., Sludden J., Brown O., Et al., Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects, Br J Clin Pharmacol, 46, 2, pp. 151-156, (1998)
[7] Raida M., Schwabe W., Hausler P., Van Kuilenburg A.B.P., Van Gennip A.H., Behnke D., Hoffken K., Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls, Clinical Cancer Research, 7, 9, pp. 2832-2839, (2001)
[8] Schwab M., Zanger U.M., Marx C., Et al., Role of genetic and nongenetic factors for fluorouracil-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group, J Clin Oncol, 26, 13, pp. 2131-2138, (2008)
[9] Braun M.S., Richman S.D., Quirke P., Et al., Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial, J Clin Oncol, 26, 16, pp. 2690-2698, (2008)
[10] McLeod H.L., Sargent D.J., Marsh S., Et al., Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741, J Clin Oncol, 28, 20, pp. 3227-3233, (2010)

← 1 2 3 4 →